Abiopharma

News list

Blume-Jensen Peter 🔴 sold 1.7K shares of Acrivon Therapeutics, Inc. (ACRV) at $2.01 Transaction Date: Aug 18, 2026 | Filing ID: 003836

Full text

News bot Aug. 20, 2026, 8:07 p.m.
🔍 Blume-Jensen Peter (Executive)

Company: Acrivon Therapeutics, Inc. (ACRV)

Report Date: 2026-08-18
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 0
- Holdings reported: 0
- Total shares sold: 1,713
Detailed Transactions and Holdings:
- Sold 1,229 shares of Common Stock at $2.01 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 2,244,088.00 | transaction_form_type: 4 | Footnotes: F1, F2
- Sold 484 shares of Common Stock at $2.01 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 385,859.00 | transaction_form_type: 4 | Footnotes: F1, F3
Footnotes:
- F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- F2: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- F3: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.